ROIV - Roivant Sciences: Executing On Huge Buyback Program With More To Come
2024-06-02 07:27:01 ET
Summary
- Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash.
- The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus.
- Genevant and Arbutus offer potential litigation value of $5-10 billion against Moderna and Pfizer.
In the final quarter of 2023, Roivant Sciences ( ROIV ) sold its stake in Televant in a $5.3 billion dollar deal to big pharma (which I wrote about here ). Surprisingly, the stock sold off. Yesterday, the company reported earnings and I figured it would be a good time to update my view. Spoiler; I still think the stock is quite undervalued and I remain long....
Roivant Sciences: Executing On Huge Buyback Program With More To Come